Insmed Shares Rise on Positive Results from Lung-Infection Drug Study

Dow Jones03-23

By Connor Hart

Shares of Insmed climbed after the company disclosed what it called positive topline results from a late-stage study of its treatment for certain lung infections.

The stock rose 10%, to $150.02, in premarket trading Monday. Shares are up more than 71% over the past year through Friday's close, despite having lost more than a fifth of their value over the past three months.

The biopharmaceutical company said before the bell that its treatment, amikacin liposome inhalation suspension, demonstrated statistically significant and clinically meaningful improvements for patients with a new occurrence of Mycobacterium avium complex, or MAC, lung infection, when used in combination with an existing multidrug therapy.

"These results are an exciting win for patients living with MAC lung disease," said Chief Medical Officer Martina Flammer, adding that the treatment has the ability to deliver "real clinical benefit as part of a multidrug treatment regimen."

Insmed said it plans to file a supplemental new drug application for the therapy in the second half of 2026 to support potential label expansion and to obtain traditional approval for the existing refractory indication in the U.S.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

March 23, 2026 09:06 ET (13:06 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621370641?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621370641","market":"sg","top_or_hot":-1,"title":"Insmed Shares Rise on Positive Results from Lung-Infection Drug Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/INSM\">Insmed</a> climbed after the company disclosed what it called positive topline results from a late-stage study of its treatment for certain lung infections. \n</p>\n<p>\n  The stock rose 10%, to $150.02, in premarket trading Monday. Shares are up more than 71% over the past year through Friday's close, despite having lost more than a fifth of their value over the past three months. \n</p>\n<p>\n  The biopharmaceutical company said before the bell that its treatment, amikacin liposome inhalation suspension, demonstrated statistically significant and clinically meaningful improvements for patients with a new occurrence of Mycobacterium avium complex, or MAC, lung infection, when used in combination with an existing multidrug therapy. \n</p>\n<p>\n  \"These results are an exciting win for patients living with MAC lung disease,\" said Chief Medical Officer Martina Flammer, adding that the treatment has the ability to deliver \"real clinical benefit as part of a multidrug treatment regimen.\" \n</p>\n<p>\n  Insmed said it plans to file a supplemental new drug application for the therapy in the second half of 2026 to support potential label expansion and to obtain traditional approval for the existing refractory indication in the U.S. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 23, 2026 09:06 ET (13:06 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insmed Shares Rise on Positive Results from Lung-Infection Drug Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsmed Shares Rise on Positive Results from Lung-Infection Drug Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-23 21:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/INSM\">Insmed</a> climbed after the company disclosed what it called positive topline results from a late-stage study of its treatment for certain lung infections. \n</p>\n<p>\n  The stock rose 10%, to $150.02, in premarket trading Monday. Shares are up more than 71% over the past year through Friday's close, despite having lost more than a fifth of their value over the past three months. \n</p>\n<p>\n  The biopharmaceutical company said before the bell that its treatment, amikacin liposome inhalation suspension, demonstrated statistically significant and clinically meaningful improvements for patients with a new occurrence of Mycobacterium avium complex, or MAC, lung infection, when used in combination with an existing multidrug therapy. \n</p>\n<p>\n  \"These results are an exciting win for patients living with MAC lung disease,\" said Chief Medical Officer Martina Flammer, adding that the treatment has the ability to deliver \"real clinical benefit as part of a multidrug treatment regimen.\" \n</p>\n<p>\n  Insmed said it plans to file a supplemental new drug application for the therapy in the second half of 2026 to support potential label expansion and to obtain traditional approval for the existing refractory indication in the U.S. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 23, 2026 09:06 ET (13:06 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2621370641","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621370641","pubTimestamp":1774271160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Insmed climbed after the company disclosed what it called positive topline results from a late-stage study of its treatment for certain lung infections.The stock rose 10%, to $150.02, in premarket trading Monday. Shares are up more than 71% over the past year through Friday's close, despite having lost more than a fifth of their value over the past three months.The biopharmaceutical company said before the bell that its treatment, amikacin liposome inhalation suspension, demonstrated statistically significant and clinically meaningful improvements for patients with a new occurrence of Mycobacterium avium complex, or MAC, lung infection, when used in combination with an existing multidrug therapy.\"These results are an exciting win for patients living with MAC lung disease,\" said Chief Medical Officer Martina Flammer, adding that the treatment has the ability to deliver \"real clinical benefit as part of a multidrug treatment regimen.\". Insmed said it plans to file a supplementa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","INSM":"Insmed","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"Insmed股价因肺部感染药物研究取得积极结果而上涨","themeId":"8603dabb40994e59ac78c04c930c0d49","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1.5},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Insmed climbed after the company disclosed what it called positive topline results from a late-stage study of its treatment for certain lung infections. \n\n\n  The stock rose 10%, to $150.02, in premarket trading Monday. Shares are up more than 71% over the past year through Friday's close, despite having lost more than a fifth of their value over the past three months. \n\n\n  The biopharmaceutical company said before the bell that its treatment, amikacin liposome inhalation suspension, demonstrated statistically significant and clinically meaningful improvements for patients with a new occurrence of Mycobacterium avium complex, or MAC, lung infection, when used in combination with an existing multidrug therapy. \n\n\n  \"These results are an exciting win for patients living with MAC lung disease,\" said Chief Medical Officer Martina Flammer, adding that the treatment has the ability to deliver \"real clinical benefit as part of a multidrug treatment regimen.\" \n\n\n  Insmed said it plans to file a supplemental new drug application for the therapy in the second half of 2026 to support potential label expansion and to obtain traditional approval for the existing refractory indication in the U.S. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 23, 2026 09:06 ET (13:06 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621370641","isCrawlerRequest":true}